New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer (original) (raw)
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
Jordi Remon, E. Dalmau
2014
View PDFchevron_right
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Laura Bonanno
Current Drug Targets, 2011
View PDFchevron_right
Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer
Junichi Soh
Acta medica Okayama, 2014
View PDFchevron_right
Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Giannis Mountzios
Annals of Translational Medicine
View PDFchevron_right
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Carminia Maria Della Corte
ESMO open, 2016
View PDFchevron_right
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance
Glenwood Goss
Translational Lung Cancer Research, 2016
View PDFchevron_right
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
Takeshi Isobe
Cells
View PDFchevron_right
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
Giuseppe Lo Russo
Tumori, 2017
View PDFchevron_right
Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
Radosław Mlak
Współczesna Onkologia, 2012
View PDFchevron_right
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Giannis Mountzios
Cancers
View PDFchevron_right
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Maria Arcila
Clinical Cancer Research, 2011
View PDFchevron_right
Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer
Godefridus J Peters
View PDFchevron_right
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Maria Arcila
Clinical Cancer Research, 2013
View PDFchevron_right
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Mark Vincent
Frontiers in Oncology, 2017
View PDFchevron_right
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Amelia D'Alessio
Expert opinion on therapeutic targets, 2016
View PDFchevron_right
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Nam Nghia Bui
Molecular cancer therapeutics, 2017
View PDFchevron_right
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Gregory Riely
Clinical Cancer Research, 2006
View PDFchevron_right
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Subba Digumarthy
Science Translational Medicine, 2011
View PDFchevron_right
Latest Treatment Options to Overcome Acquired Resistance Toosimertinib for Egfr-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior Egfr-Tki Therapies
Lukman Tijani
2019
View PDFchevron_right
Molecular Mechanisms Contributing Resistance to Tyrosine Kinase-Targeted Therapy inin Non-Small Cell Lung Cancer
Fariz Nurwidya
Cancer Biology and Medicine. 2012;9:18 - 22
View PDFchevron_right
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer
Deb Ayeni
Clinical Cancer Research
View PDFchevron_right
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review
Corey Carter
Neoplasia (New York, N.Y.), 2018
View PDFchevron_right
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
maricla galetti
Current Pharmaceutical Design, 2012
View PDFchevron_right
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance
Matthias Scheffler
View PDFchevron_right
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Junia C Costa
Lung Cancer
View PDFchevron_right
Overcoming Resistance to EGFR Inhibitors in NSCLC
Samir Witta
Reviews on Recent Clinical Trials, 2016
View PDFchevron_right
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
pei-chih lee
Cancer Cell, 2018
View PDFchevron_right
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao C
PLOS Medicine, 2005
View PDFchevron_right
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Roberto Bianco
Endocrine Related Cancer, 2005
View PDFchevron_right
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Sai-Hong Ou
Molecular Cancer Therapeutics, 2012
View PDFchevron_right
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
Chi-li Chung
PLoS ONE, 2013
View PDFchevron_right
EGFR-tyrosine kinase mutations in non-small cell lung cancer-based responsiveness to anti-cancer therapy
Editor VISNAV
Visnav, 2021
View PDFchevron_right
Data from The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Sai-Hong Ou
View PDFchevron_right
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
Po-Lan Su
Frontiers in Oncology, 2020
View PDFchevron_right